Press Release – Playa Vista, California and Salt Lake City, Utah (PRBUZZ) – December, 28th, 2017 – Today Leonhardt’s Launchpads, an innovation accelerator focused on organ regeneration technologies, announced a technology showcase Monday January 8th, 2018 at WeWork SoMa, 156 2nd St, San Francisco, CA 94105 @ 5pm to 6:30pm (less than 1 mile from JP Morgan Healthcare Conference). Leonhardt’s Launchpads has startup support and innovation acceleration labs in Northern and Southern California as well as in Salt Lake City, Utah and currently incubates 27 organ regeneration and recovery focused startups. These startups and their innovations will be showcased with short pitches on each with followup time for questions. The sessions about 12 minutes each in order will be Heart & Cardiovascular, Brain, Cosmetic & Personal Care, Major Organ Regeneration and Cancer.
Links to web sites, slide decks and videos for each startup may be reached via www.leonhardtventures.com ; Most of the startups are based on the core technologies of bioelectric stimulation controlled release of proteins (including stem homing, proliferation and differentiation signals), a re-fillable micro infusion pump and a mixed organ regeneration composition comprised of stem cells, growth factors, exosomes, Micro RNAs, selected alkaloids, nutrient hydrogel and organ specific matrix.
HEART AND CARDIOVASCULAR
BioLeonhardt – total heart regeneration.
AortaCell – aorta regeneration.
BioPace – biological pacemaker regeneration.
Valvublator – heart valve decalcification and regeneration.
VibroCell (includes CoroStim) – vibrational energy to prevent clots, plaque, calcification.
HeartScore – genomics and bioelectric based heart failure, inflammation and stroke management.
VascuStim (formerly MyoStim Peripheral, includes EndoCell) – limb salvage regeneration, blood flow improvement for critical limb ischemia, diabetic leg and foot ulcer treatment, artery regeneration.
Second Heart Assist, Inc. – wireless powered chronic or temporary circulatory assist pump in aortic stents
PressureStim – bioelectric treatment of high blood pressure via improved arterial elasticity and bioelectric membrane potentials management.
BRAIN
CerebraCell (includes CerebraCell Brain-N-Hance and CerebraCell Concussion) – brain regeneration, cognitive function improvement, concussion recovery.
COSMETIC and PERSONAL CARE
Stem Cell Bra – breast regeneration.
DentaCell Accelerator – innovation accelerator focused on dentistry based on bioelectric, stem cell, growth factor and holistic approaches.
OrthodontiCell – bioelectric stimulator for accelerated tooth movement and stablization.
SkinCell Stimulator by MyoStim Skin – skin regeneration.
MyoStim ED – bioelectric erectile dysfunction treatment.
HairCell – hair regeneration.
MAJOR ORGAN REGENERATION
EyeCell – eye regeneration.
PancreaCell – pancreas regeneration.
RegenaLung (includes ECMO-Cath) – lung regeneration and ARDS treatment (includes 50% owned subsidiary RegenaLung COPD).
LiverCell – liver regeneration.
KidneyCell – kidney regeneration.
EarCell – ear hearing regeneration.
BladderCell – bladder regeneration.
MucosaCell – sub-mucosa regeneration.
InStim – bioelectric real time inflammation management
BioLeonhardt Whole Body Regeneration – whole body regeneration and Bod-Stim bioelectric yoga and athletic pants.
CANCER TREATMENT
CancerCell – bioelectric cancer tumor treatment + regeneration.
Leonhardt’s Launchpads startups announced earlier this year…
> License agreement for IP estate for bioelectric cancer tumor treatment from Neuro Code Tech Holdings.
> Filing of new patents pending for multiple modality bioelectric cancer tumor treatment.
> Launch of InStim startup focused on real time bioelectric inflammation monitoring and management.
> Launch of PressureStim and licensing of patents for bioelectric blood pressure control.
> $1 million raised for startup Second Heart Assist, Inc. and launch of pre-clinical studies.
> License agreement with Caltech for IP estate related to circulatory assist support.
> Launch of VascuStim clinical research program for diabetic ulcer treatment.
> Launch of DentaCell Accelerator focused on accelerating dentistry innovations.
> Patent filing for vibration harmonic resonance technology to prevent blood clots, calcification and plaque formations on blood contact surfaces.
> Patent filings for controlled expression of PDGF, HIF1 alpha, CXCL5 and other key regeneration promoting proteins.
See https://leonhardtventures.com/news/ to links to previous news stories. Leonhardt’s Launchpads startups filed over 75 new U.S. patent claims in 2017.
About Leonhardt’s Launchpads:
Operated by Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures and inventor Howard J. Leonhardt. The five year accelerator is incubating 27 regenerative medtech and 3 regenerative economy startups and licensable technology platforms (LTPs). The accelerator has affiliated offices and labs in Santa Monica, Petaluma, Playa Vista, Torrance and Pasadena, California and in Salt Lake City, Utah. Life science incubator/accelerator operations began in 2008 at the University of Northern California Science & Technology Innovation Center (UNC STIC) in Santa Rosa, California under Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures founded in 2005). In 2013 the organization was incorporated and moved its headquarters to Santa Monica, California and in 2017 expanded to Playa Vista, California where its primary headquarters are now.
About Leonhardt’s Launchpads Utah, Inc.:
Founded in November 2015 in Salt Lake City, Utah, just off the campus of the University of Utah, is an organ regeneration focused innovation and startup accelerator. The company has lab space at the USTAR BioInnovations Gateway Utah facility at 2500 S. State Street, Salt Lake City, Utah and employs 5 biomedical engineers and biologists at this time and has recruited a half dozen local Utah based advisors.
About Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures):
Founded in 1982 as a sole proprietorship is the patent holding vehicle and venture capital arm of inventor Howard J. Leonhardt (formed into Califiornia LLC in 2005). In the 1980’s Leonhardt patented and developed a market leading cardiovascular balloon catheter, in the 1990’s the leading stent graft system for endovascular aortic aneurysm repair and one of the first percutaneous heart valves and biological pacemakers. Since 2000 the focus has been on organ regeneration technologies with a combination of bioelectric signaling and repeat delivery of mixed stem cell + growth factor based compositions. More recently Leonhardt has added a strong estate of IP related to bioelectric cancer tumor treatment, real time inflammation and blood pressure management as well as a “brain saving helmet” designed for cerebral stroke patients. Leonhardt has over 21 U.S. Patents with over 100 issued patent claims and dozens more pending. Leonhardt inventions have been used to treat more than 400,000 patients to date.
Cautionary Note Regarding Forward-Looking Statements:
Statements in this press release regarding the efficacy, safety, and intended utilization of Leonhardt’s Launchpads product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads, Leonhardt Vineyards LLC DBA Leonhardt Ventures, or Leonhardt’s Launchpads Utah, Inc. management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our 506D part C Cal-X Stars Business Accelerator, Inc. private placement memorandum originally filed in 2013 and updated via our Annual Reports. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.
Web Site:
Leonhardt Ventures www.leonhardtventures.com – this site includes links to all portfolio startup individual web sites.
